BWX Limited Overview
At its peak BWX Limited was Australia's leading listed pure-play in natural beauty and personal care: a vertically integrated developer, manufacturer, distributor and marketer of branded skin, body and hair care, built around the mass-market natural brand Sukin and extended through acquisitions into the United States (Andalou Naturals, Mineral Fusion), direct-to-consumer ethical e-commerce (Nourished Life, Flora & Fauna) and a majority stake in celebrity-founded Go-To Skincare. Its thesis was compelling — a structurally growing "clean" category, owned manufacturing in Victoria, and wide grocery and pharmacy distribution through Coles, Woolworths and Chemist Warehouse. Execution failed. Serial acquisitions, an ERP disruption, China export softness, a costly new Clayton factory, retailer destocking, revenue-recognition problems and a A$322.6 million intangible write-down in FY2022 left the group over-levered to CBA. It collapsed into administration in April 2023, was broken up and sold brand by brand, and is now a liquidated shell with no operating business.
What the company did. BWX described itself in its ASX materials as a vertically integrated developer, manufacturer, distributor and marketer of branded personal care products with an emphasis on the natural segment of the market (North Castle Partners release on the Mineral Fusion sale; Motley Fool company profile). Its later investor framing, used in its August 2021 CEO Connect presentation, was "natural beauty and wellness for the world."
Business model. BWX was a branded consumer-products owner. Value creation came from (a) formulating natural-positioned products, (b) manufacturing a large share of volume in-house in Victoria (Dandenong South, then a new facility at Clayton), (c) selling wholesale to grocery, pharmacy and specialty retailers in Australia, the US, Canada and export markets, and (d) selling direct-to-consumer through owned e-commerce platforms (Nourished Life from 2017; Flora & Fauna from 2021) that also stocked third-party brands.
Revenue model mix. Essentially 100% product revenue. There was no subscription, licensing or service revenue of significance. Within product revenue, the mix was:
Value-chain position. Mid-to-upstream: product development, contract and owned manufacturing, brand marketing, and wholesale distribution, with a partial move downstream into owned retail via e-commerce marketplaces.
Customer types and end-markets. Mass grocery (Coles from September 2017; Woolworths), pharmacy (Chemist Warehouse strategic partnership; Priceline), natural specialty grocery in North America (Whole Foods Market, Sprouts Farmers Market), mass retail in Canada (Walmart Canada), cross-border Chinese e-commerce, and end consumers directly via online stores. End-market: natural and "clean" beauty and personal care (skincare, body care, hair care, cosmetics), adjacent ethical household, baby and pet products via Flora & Fauna.
Independent characterisation. BWX was a sub-scale consumer roll-up with one genuinely strong local asset (Sukin, a top-selling natural skincare brand in Australian supermarkets and pharmacy) surrounded by acquired brands bought at full prices with debt and equity. The portfolio lacked operating synergy: US brands sold through different channels than Sukin, Go-To was explicitly run independently and did not use BWX manufacturing, and the e-commerce marketplaces were low-margin retail businesses grafted onto a manufacturer. The model depended on continuous growth to service acquisition goodwill and capex; when retailer destocking, inflation and execution failures hit in FY2022, the leverage and intangible-heavy balance sheet left no buffer.
Strategy
Stated strategy (last active period, FY2021–FY2022). BWX's August 2021 materials articulated a "natural beauty and wellness for the world" vision with a multi-year strategic roadmap whose themes were: (1) leverage the structural shift toward natural, ethical and purpose-driven consumption; (2) accelerate core brands Sukin, Andalou Naturals and Mineral Fusion through strategic retail partnerships (Chemist Warehouse, Woolworths, Walmart Canada); (3) build a direct-to-consumer business unit, led by Julie Mathers, combining Flora & Fauna and Nourished Life into an ethical online retail platform; (4) add a premium skincare engine via the Go-To partnership; and (5) bring manufacturing capacity in-house at the Clayton facility from December 2021.
Initiatives in the final 24 months of operation
Medium-term targets. The last formal targets were FY2023 guidance of A$260–270m revenue and A$45–49m EBITDA (28 June 2022), cut in early 2023 to A$170–190m revenue (from an intermediate A$205–230m) with 2H FY2023 EBITDA of A$5–12m. None were met.
Products & Services
All brands below are now owned by third parties; ownership after BWX is noted.
Pricing models were standard wholesale/retail pricing; individual SKU price architecture was not publicly disclosed by BWX.
Product Portfolio
| Brand | Category / description | Target customer | Launch | Channels under BWX | Pricing tier | Current owner |
|---|---|---|---|---|---|---|
Sukin | Natural skin, body and hair care; flagship mass-natural brand; carbon-neutral and vegan positioning | Mass-market Australian consumers seeking affordable natural products | 2,007 | Coles, Woolworths, Chemist Warehouse, pharmacy, export incl. China cross-border, US (from 2H FY18) | Mass / value-natural | PNB Consolidated (John Humble), from Jan 2024 |
Derma Sukin | Sensitive-skin / dermatological extension of Sukin | Sensitive-skin consumers | — | Pharmacy, grocery | Mass | Transferred with Australian business (not separately confirmed) |
Andalou Naturals | Fruit stem-cell science skincare and hair care; first Non-GMO Project Verified beauty brand; 125+ SKUs | Premium natural-channel shoppers in North America, Europe, Asia | 2,010 | Whole Foods, Sprouts, natural specialty, mass expansion | Premium natural | The Seaweed Bath Co., from Jul 2024 |
Mineral Fusion | Mineral cosmetics plus hair, body, skin and nail care; hypoallergenic, free of gluten, parabens, phthalates, synthetic fragrance, talc; primarily vegan; EWG-verified | Clean-beauty cosmetics buyers | 2,007 | ~3,000 stores incl. Whole Foods at acquisition; own e-commerce | Mid / premium | The Seaweed Bath Co., from Jul 2024 |
Nourished Life | Online natural and organic beauty and wellness marketplace; ~3,500 SKUs at acquisition | Australian online ethical shoppers | Founded by Irene Falcone; acquired 2017 | Own website, club membership | Marketplace | Julie Mathers / HealthPost, from Apr 2023 |
Life Basics | Nourished Life private label (launched Feb 2017); also a natural hand sanitiser launched in 2020 | Nourished Life customers | 2,017 | Nourished Life | Value | Transferred with Nourished Life |
Flora & Fauna | Online ethical, vegan, cruelty-free marketplace; ~10,000 SKUs across 10 categories (beauty, personal care, lifestyle, baby and kids, pet, food and health); ~94,000 active customers; Sydney warehouse store opened 2019 | Purpose-driven younger consumers | 2,014 | Own website | Marketplace | Julie Mathers / HealthPost, from Apr 2023 |
Go-To Skincare (50.1%) | Simple, efficacious premium skincare founded by Zoë Foster Blake; independently managed; did not use BWX manufacturing | Premium skincare consumers, Australia and international | 2,014 | Mecca, own DTC, international | Premium | Zoë Foster Blake and Paul Bates, from Dec 2023 |
USpa | Spa-style body care | Mass | — | Grocery/pharmacy | Mass | — |
Edward Beale | Hair care | Mass | — | Grocery/pharmacy | Mass | — |
Renew Skincare | Skincare | Mass | — | Grocery/pharmacy | Mass | — |
Purely Byron (48% investment) | Beauty brand co-founded by Elsa Pataky | Premium | — | — | Premium | Entered administration (DW Advisory) in early 2023 |
Sukin natural hand sanitiser | Rapid COVID-19 product launch | Mass | 2,020 | Grocery, pharmacy, online | Mass | With Sukin |
Financial Narrative
Scope: The last five fiscal years for which BWX reported full-year numbers are FY2018–FY2022. BWX never published FY2023 results; the only FY2023 data is 1H FY2023 and guidance.
Income statement
Sources and notes:
-
FY2018: Kalkine Media, 29 Aug 2018 (revenue, underlying EBITDA, statutory NPAT A$19.2m, basic EPS 17c, total dividend 7.45c fully franked). Underlying NPAT was A$24.2m (Kalkine, Oct 2018). FY2018 growth of 105% per Kalkine; acquisitions contributed ~A$79m.
-
FY2019 and FY2020: BWX FY2020 results release (ASX, 21 Aug 2020). FY2020 EBITDA A$27.5m pre-AASB 16; A$30.9m post-AASB 16.
-
FY2021: Finance News Network report of BWX FY2021 results (revenue A$194.1m, EBITDA A$34.5m, NPAT A$23.7m, final dividend 3.1c).
-
FY2022: Business News Australia reporting of audited FY2022 results. Conflict: the 28 June 2022 guidance had indicated ~A$206m revenue and A$6–10m EBITDA; audited revenue came in at A$198.3m and EBITDA at -A$6.4m. The A$335.6m statutory loss included a A$322.6m non-cash intangible impairment.
Margins (%)
Margins computed from table 6.1 values (FY2020 EBITDA margin on the pre-AASB 16 basis).
Revenue CAGR FY2018–FY2022: approximately 7.5% per annum (A$148.7m to A$198.3m over four years). Excluding acquired revenue, organic growth was substantially lower; Sukin organic growth in FY2018 was only 6.1% (Kalkine).
Half-year data, final reporting periods
Notes: 1H FY2018 normalised figures per Motley Fool (Mar 2018). 1H FY2020 per BWX release (underlying NPAT A$4.2m). 1H FY2021 per Kalkine. 1H FY2023 per Business News Australia (Feb 2023); revenue fell 18.4% and 1H FY2022 revenue (≈A$97.7m) is derived from that decline rate. 1H FY2022 EBITDA and loss values are as quoted in the 1H FY2023 comparison.
Balance sheet
Notes: FY2018 net cash A$19.89m and D/E 0.19x per Kalkine (Oct 2018). FY2019 net cash ~A$12m per BWX 1H FY2020 release (which reported net cash rising to A$14m at 31 Dec 2019). FY2022 value is the midpoint of the A$58–62m pro-forma net debt guided on 28 June 2022 (post-raise basis). Intangibles rose by more than 50% to about A$465m at 31 Dec 2021 from about A$300m a year earlier (ShareCafe, June 2022) — the base for the A$322.6m FY2022 impairment. At administration, net bank debt was reported at about A$120m (Power Retail) and debts owed to CBA at almost A$105m (Personal Care Insights) — a discrepancy likely reflecting gross vs. net measures and timing. At 31 Dec 2022, current assets exceeded current liabilities by A$14.2m, but only because CBA had granted an unconditional covenant waiver.
Cash flow
Notes: 1H FY2021 operating cash flow was A$9.81m (Kalkine). Buybacks: none identified.
Ratios
Directionally: ROE turned massively negative in FY2022 given a statutory loss exceeding A$335m against an equity base that had been inflated by acquisition intangibles; net debt/EBITDA became undefined (negative EBITDA) in FY2022, which is why CBA had to suspend covenant testing for the 30 June and 30 September 2022 test dates.
Commentary on trends and inflections
FY2018 — the high-water mark. Revenue doubled on acquisitions and underlying EBITDA margin reached about 27%, a premium level for personal care, driven by Sukin's high-margin domestic and export sales. But the quality was already deteriorating: Sukin's growth decelerated from 59% to 17% half-on-half (1H FY2018), and EBITDA landed below the A$42–48m guidance range.
FY2019 — first break. Revenue flatlined at A$149.5m and EBITDA fell nearly half to A$21.3m. Three drivers were disclosed in the December 2018 update: softer export sales into China (amid the US–China trade war), loss of momentum in the US brands during a management transition, and Sukin ERP start-up problems. A second downgrade followed as unprofitable promotions and excess stock were cycled.
FY2020–FY2021 — COVID-era recovery. Under Dave Fenlon revenue rose 26% to A$187.7m in FY2020 with Sukin up 55%, aided by distribution gains and a quickly launched hand sanitiser. FY2021 delivered A$194.1m revenue and A$23.7m NPAT, with new partnerships at Chemist Warehouse, Woolworths and Walmart Canada. However, revenue growth slowed to ~3%, and some FY2021 revenue was later questioned for recognition timing.
FY2022 — collapse. Management guided in May 2022 to A$233–243m revenue and A$27–30m EBITDA; by June that had fallen to ~A$206m and A$6–10m; audited results showed A$198.3m revenue, negative A$6.4m EBITDA and a A$335.6m statutory loss. Drivers: retailer destocking, inflation and a cautious consumer, the Chemist Warehouse equity-linked expense, acquisition costs, integration failures and Clayton capex. Remarkably, management simultaneously guided FY2023 revenue of A$260–270m and EBITDA of A$45–49m, which commentators at the time viewed as implausible.
1H FY2023 — terminal. Revenue fell 18.4% to A$79.7m and EBITDA was negative A$29.7m. Out-of-stocks (from working-capital constraint) compounded destocking, and the full-year revenue guide was cut first to A$170–190m and then implicitly abandoned. Administration followed within six weeks of the result.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Reporting Structure by Period
| Period | Reporting structure (as disclosed / referenced) |
|---|---|
FY2016–FY2017 | Effectively single-brand (Sukin) with domestic and export reporting |
FY2018–FY2020 | Brand-based disclosure: Sukin, Andalou Naturals, Nourished Life, Mineral Fusion, other brands |
FY2021–FY2022 | Brand-based disclosure plus Go-To and Flora & Fauna; operating segments by channel/geography |
1H FY2023 (final) | Commentary references Australia, International, Digital and USA business segments, plus Go-To |
Revenue by Segment
| Brand (AUD Mn) | FY2019 | FY2020 |
|---|---|---|
Sukin net sales | 52.7 | 81.7 |
Andalou Naturals net sales | 48.5 | 53.3 |
Nourished Life net sales | 21.0 | 24.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Half-Yearly)
| Brand (AUD Mn) | 1H FY2019 | 1H FY2020 |
|---|---|---|
Sukin | 23.2 | 33.1 |
Andalou Naturals | 22.7 | 26.2 |
Nourished Life | 10.8 | 11.3 |
Group Entities
| Entity | ACN | Role |
|---|---|---|
BWX Limited | 163 488 631 | Listed parent |
Beautiworx Pty Ltd | 163 847 916 | Main operating company |
LHS No. 2 Pty Ltd | 165 455 201 | Holding entity |
Sapu Corporation Pty Ltd (formerly Uspa Corporation) | 163 273 514 | USpa brand entity |
Edward Beale Hair Care Pty Ltd | 167 891 161 | Edward Beale brand |
BWX Brands Pty Ltd | 602 062 117 | Brand holding |
BWX Australia Pty Ltd | 601 966 170 | Australian operations |
Sukin Australia Pty Ltd | 602 062 199 | Sukin brand |
Renew Skin Care Australia Pty Ltd | 606 139 315 | Renew brand |
Derma Sukin Australia Pty Ltd | 606 140 818 | Derma Sukin brand |
Lightning Distribution Pty Ltd | 610 861 455 | Distribution |
BWX Digital Pty Ltd | 621 403 370 | Nourished Life / digital |
The Good Collective Pty Ltd | 169 556 398 | Flora & Fauna |
Income Statement and Margin Analysis (%)
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Net revenue (AUD Mn) | 148.7 | 149.5 | 187.7 | 194.1 | 198.3 |
Revenue growth YoY (%) | 105.0 | 0.5 | 25.6 | 3.4 | 2.2 |
EBITDA, underlying/normalised (AUD Mn) | 40.3 | 21.3 | 27.5 | 34.5 | -6.4 |
Statutory NPAT (AUD Mn) | 19.2 | 9.5 | 15.2 | 23.7 | -335.6 |
Basic EPS (AUD cents) | 17.0 | — | — | — | — |
Dividends per share (AUD cents) | 7.45 | — | — | — | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
EBITDA margin (%) | 27.1 | 14.2 | 14.7 | 17.8 | -3.2 |
Net margin (%) | 12.9 | 6.4 | 8.1 | 12.2 | -169.2 |
Income Statement
| Metric | 1H FY2018 | 1H FY2020 | 1H FY2021 | 1H FY2022 | 1H FY2023 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 67.2 | 84.1 | 84.5 | 97.7 | 79.7 |
EBITDA (AUD Mn) | 17.5 | — | — | 5.4 | -29.7 |
Statutory NPAT (AUD Mn) | — | — | 9.85 | -5.4 | -100.8 |
Key Financials and Financial Ratios (x)
| Metric | FY2018 | FY2019 | FY2022 |
|---|---|---|---|
Net cash (+) / net debt (-) (AUD Mn) | 19.9 | 12.0 | -60.0 |
Debt to equity (x) | 0.19 | — | — |
Balance Sheet
| Metric | FY2021 | FY2022 |
|---|---|---|
Equity raised (AUD Mn) | 100.0 | 23.2 |
Valuation Snapshot
| Metric | Value |
|---|---|
Listing date | 11 November 2015 |
Price on 8 Aug 2018 | A$4.99 (market cap ~A$665m) |
Price on FY2021 result (pre-halt, Aug 2021) | A$5.31 |
2022 high | A$5.56 |
June 2022 capital raise price | A$0.60 |
Price at June 2022 (post-announcement) | A$0.695 (Market Matters) |
Last vendor-quoted price (1 May 2024) | A$0.20 (InvestSMART; delisted) |
1-, 3-, 5-year return to Oct 2026 | Not meaningful — delisted; equity value effectively nil |
Per-Share Data
| Metric | FY2018 | FY2021 | FY2022 |
|---|---|---|---|
Total DPS (AUD cents) | 7.45 | — | 0 |
Final DPS (AUD cents) | 4.2 | 3.1 | 0 |
Analyst Conclusions
Management guidance / consensus: None. The company is in liquidation, has no operating business, no management, and no analyst coverage. The only remaining value-relevant events are the liquidators' final distributions and eventual deregistration.
Bull-case arguments (for the brands, not the shell)
-
Sukin retained franchise value: the brand plus factory realised roughly A$70m in a contested process, and its founder repurchased it, suggesting confidence in its standalone economics.
-
Andalou and Mineral Fusion were acquired as a platform by The Seaweed Bath Co. with Natureza Growth Partners backing, implying the US brands remain viable.
-
Go-To and Flora & Fauna returned to founder ownership, which historically suits founder-led brands.
Bear-case arguments (for BWX Limited equity and unsecured creditors)
-
Secured debt of roughly A$105–120m to CBA ranks ahead of everyone, and disclosed realisations (A$21.8m Go-To plus ~A$70m Sukin) plus undisclosed digital and US proceeds give little visible surplus after receivers' and administrators' costs.
-
Ordinary shareholders rank last in liquidation; recovery is very likely nil.
-
The company has been delisted and its operating subsidiaries sold, so there is no residual business to recapitalise.
Catalysts and monitorables (next 12 months)
-
Any further liquidators' reports or dividend notices to creditors (FTI creditors portal).
-
Any public examination, insolvent-trading or voidable-transaction claims arising from the 9 August 2024 statutory report.
-
Any ASIC action relating to FY2021–FY2022 financial reporting.
-
Deregistration of BWX Limited and its subsidiaries.
-
Performance of the successor owners: Sukin under PNB Consolidated; Andalou and Mineral Fusion under Seaweed Bath Co.
Concluding analyst verdict
BWX Limited is a closed case rather than an investment proposition. The listed entity has no assets of operating substance, no listing, no management and no prospect of equity recovery, and it should be treated in any coverage universe as a written-off, liquidated holding. The analytical value of the dossier lies in the lessons. BWX demonstrates how a genuinely good domestic brand can be overwhelmed by the capital structure built around it. Sukin was profitable, well distributed and loved enough by consumers that its founder paid around A$70 million to buy it back out of receivership. Yet between 2017 and 2021 the group layered on Andalou Naturals, Mineral Fusion, Nourished Life, Flora & Fauna and a 50.1% stake in Go-To at full prices, funded by bank debt and dilutive equity, while committing to a new factory. Each acquisition widened the gap between headline revenue growth and organic performance, and intangibles swelled to around A$465 million on a business that never earned more than about A$40 million of EBITDA. When FY2022 brought retailer destocking, inflation, an expensive pharmacy partnership and accounting problems with revenue recognition, earnings vanished, the A$322.6 million impairment followed, and the lender's patience ran out within ten months. Governance signals were visible well before the end: repeated guidance misses from 2018 onward, a failed management buyout, rapid CEO turnover, and wildly optimistic FY2023 targets issued alongside an emergency raise. The receivers then realised a fraction of what had been paid: Go-To returned for A$21.8 million against roughly A$89 million invested. For investors in consumer roll-ups, BWX is a textbook warning about paying for growth with leverage, the fragility of retailer-dependent revenue, and the importance of separating organic from acquired growth. Final verdict: no investment case; equity value nil; monitor only for liquidation outcomes and any regulatory follow-up.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Notes |
|---|---|---|---|
Thinus Keeve | Group CEO & Managing Director | Appointed 27 Feb 2023 | Appointed after the 1H FY2023 result; in office at administration |
Mark (Marcus) Anthony Derwin | Non-Executive Director | Appointed 10 Feb 2023 | Board refresh during crisis |
Lisa Ronson | Non-Executive Director | Appointed 26 Feb 2023 | Previously director of The Reject Shop (since 2019) and Laybuy (since 2021) per Motley Fool profile |
Birol Akdogan | Chief Financial Officer | At least 2023 | Declined comment on Purely Byron administration |
Rory Gration | CEO | 1 Mar 2022 – Feb 2023 | Departed with immediate effect alongside the A$100.8m half-year loss |
Dave Fenlon | Group CEO & MD | c. 2019 – early 2022 | Led FY2020–FY2021 recovery and acquisitions of Flora & Fauna and Go-To |
John Humble | Founder / former CEO | To c. 2018 | Led failed Bain-backed buyout; returned in 2024 as buyer of Sukin via PNB Consolidated |
Julie Mathers | Founding CEO Flora & Fauna; led BWX's D2C unit from 2021 | 2021 – 2023 | Bought Flora & Fauna and Nourished Life back in 2023 |
Major Shareholders
| Holder | Shares | Stake (%) |
|---|---|---|
J P Morgan Nominees Australia Pty Limited | 12,315,834 | 6.16 |
HSBC Custody Nominees (Australia) Limited | 9,078,410 | 4.54 |
HSBC Custody Nominees (Australia) Limited A/C 2 | 7,958,269 | 3.98 |
National Nominees Limited | 6,167,517 | 3.08 |
Neweconomy Com Au Nominees Pty Limited (900 Account) | 2,079,869 | 1.04 |
Netwealth Investments Limited (Wrap Service A/C) | 546,254 | 0.27 |
Pacific Custodians Pty Limited (BWX Employee Sub-register) | 516,498 | 0.26 |
Competitive Landscape
Key Competitors
| Competitor | Owner | Segment overlap | Relative positioning vs BWX |
|---|---|---|---|
Burt's Bees | Clorox | US and global mass-natural | Far larger scale, US mass dominance |
Alba Botanica, Avalon Organics | Hain Celestial | US natural channel skincare | Direct Andalou rival (same founders' heritage) |
Weleda | Weleda AG | Global natural skincare | Premium heritage brand |
Jurlique | Shanghai Jahwa | Australian premium natural | Premium-priced Australian rival |
Aesop | L'Oréal (since 2023) | Premium Australian skincare | Prestige; competes with Go-To more than Sukin |
Trilogy | — | ANZ natural skincare | Pharmacy-channel rival |
QV / Ego Pharmaceuticals | Private | Australian pharmacy sensitive skin | Rival to Derma Sukin |
Nivea | Beiersdorf | Mass skincare | Mass incumbent |
Dr. Bronner's | Private | US natural body care | Natural-channel rival |
Adore Beauty, Mecca | Listed / private | Online beauty retail | Rivals to Nourished Life / Flora & Fauna |
Supermarket private label | Coles, Woolworths | Mass natural | Price pressure on Sukin |
Peer Comparison FY2022
| Metric | BWX FY2021 | BWX FY2022 |
|---|---|---|
Revenue (AUD Mn) | 194.1 | 198.3 |
Revenue growth (%) | 3.4 | 2.2 |
EBITDA margin (%) | 17.8 | -3.2 |
Recent Developments
Note: the 18 months to October 2026 contain no company-originated news because the company is in liquidation.



